Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases

Clinica Chimica Acta

Volumn 273, Issue 1, 1998, Pages 35-42

  Kashiwabara, Kosuke ^a   Nakamura, Hiroyuki ^a   Kiguchi, Toshio ^a   Matsuoka, Takeshi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Alanine aminotransferase; Aspartate aminotransferase; Hemodialysis; Liver cirrhosis; Non insulin dependent diabetes mellitus; Tumor marker

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 19 FRAGMENT; MARKER; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ALANINE TRANSAMINASE; ANTIGENS, NEOPLASM; ASPARTATE AMINOTRANSFERASES; DIABETES MELLITUS, TYPE 2; HUMANS; KERATINS; KIDNEY FAILURE, CHRONIC; LIVER CIRRHOSIS; RENAL DIALYSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0032496429     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00026-6     Document Type: Article

References (17)

1. [1] Weber K, Osborn M, Moll R, Wiklund B, Lüning B. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J 1984;11:2707-14.
2. [2] Sarwar M, Tomiyoshi K, Inoue T, Fukuzawa K, Endo K. CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay. Ann Nucl Med 1994;8:301-6.
3. [3] van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Cornillie F, Splinter TAW. Evaluation of a new tumor marker in patients with non-small-cell lung cancer: cyfra 21-1. Br J Cancer 1994;69:525-8.
4. [4] Stieber P, Dienemann H, Hasholzner U et al. Comparison of CYFRA 21-1 TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Int J Biol Markers 1994;9:82-8.
5. [5] van der Gaast A, Kok TC, Kho GS, Blijenberg BG, Splinte TAW. Disease monitoring by the tumor markers cyfra 21.1 and TPA in patients with non-small-cell lung cancer. Eur J Cancer 1995;31A:1790-3.
6. [6] Stieber P, Dienemann H, Hasholzner U et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumor markers in lung cancer. Eur J Clin Chem Clin Biochem 1993;31:689-94.
7. [7] Plebani M, Basso D, Navaglia F, Paoli MD, Tommasini A, Cipriani A. Clinical evaluation of seven tumor markers in lung cancer diagnosis: can any combination improve the results?. Br J Cancer 1995;72:170-3.
8. [8] Broers JLV, Ramaekers FCS, Rot MK et al. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res 1988;48:3221-9.
9. [9] Moll R, Franke WW, Schller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
10. [10] Rastel D, Ramaioli A, Cornillie F, Thirion B, on behalf of the CYFRA 21-1 multicentre study group . CYFRA 21-1, a sensitive and specific new tumor marker for squamous cell lung cancer. Report of the first European multicentre evaluation. Eur J Cancer 1994;30A:601-6.
11. [11] Molina R, Agusti C, Filella X et al. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Tumor Bio 1994;15:318-25.
12. [12] Björklund B, Björklund V. Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique: presence of an insoluble heat-labile tumor antigen. Int Arch Allergy 1957;10:154-84.
13. CYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 1994;9:70-4.
14. [14] Collazos J, Genollá J, Ruibal A. A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis. Digestion 1992;53:157-61.
15. [15] Leandro G, Zizzari S, Piccoli A, Manghisi OG. The serum tissue polypeptide antigen in the detection of hepatocellular carcinoma in cirrhotic patients. Hepato-Gastroenterol 1990;37:449-51.
16. [16] Mross KB, Wolfrum DI, Rauschecker H. Determination of tissue polypeptide antigen (TPA) levels in different cancer types and controls. Oncology 1985;42:288-95.
17. [17] Kew MC, Berger EL. The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma. Cancer 1986;58:127-30.